JP2023171614A5 - - Google Patents

Download PDF

Info

Publication number
JP2023171614A5
JP2023171614A5 JP2023176883A JP2023176883A JP2023171614A5 JP 2023171614 A5 JP2023171614 A5 JP 2023171614A5 JP 2023176883 A JP2023176883 A JP 2023176883A JP 2023176883 A JP2023176883 A JP 2023176883A JP 2023171614 A5 JP2023171614 A5 JP 2023171614A5
Authority
JP
Japan
Prior art keywords
oral formulation
subject
administered
oral
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023176883A
Other languages
English (en)
Japanese (ja)
Other versions
JP7688681B2 (ja
JP2023171614A (ja
Filing date
Publication date
Priority claimed from JP2018567299A external-priority patent/JP6895464B2/ja
Application filed filed Critical
Publication of JP2023171614A publication Critical patent/JP2023171614A/ja
Publication of JP2023171614A5 publication Critical patent/JP2023171614A5/ja
Priority to JP2025086125A priority Critical patent/JP2025124733A/ja
Application granted granted Critical
Publication of JP7688681B2 publication Critical patent/JP7688681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023176883A 2016-06-21 2023-10-12 アルドース還元酵素阻害剤およびその使用方法 Active JP7688681B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086125A JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662352784P 2016-06-21 2016-06-21
US62/352,784 2016-06-21
JP2018567299A JP6895464B2 (ja) 2016-06-21 2017-06-21 アルドース還元酵素阻害剤およびその使用方法
JP2021094883A JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021094883A Division JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086125A Division JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Publications (3)

Publication Number Publication Date
JP2023171614A JP2023171614A (ja) 2023-12-01
JP2023171614A5 true JP2023171614A5 (https=) 2023-12-08
JP7688681B2 JP7688681B2 (ja) 2025-06-04

Family

ID=60783884

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018567299A Active JP6895464B2 (ja) 2016-06-21 2017-06-21 アルドース還元酵素阻害剤およびその使用方法
JP2021094883A Active JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法
JP2023176883A Active JP7688681B2 (ja) 2016-06-21 2023-10-12 アルドース還元酵素阻害剤およびその使用方法
JP2025086125A Pending JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018567299A Active JP6895464B2 (ja) 2016-06-21 2017-06-21 アルドース還元酵素阻害剤およびその使用方法
JP2021094883A Active JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086125A Pending JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Country Status (21)

Country Link
US (6) US10150779B2 (https=)
EP (3) EP3757107B1 (https=)
JP (4) JP6895464B2 (https=)
CN (2) CN109310674B (https=)
AU (4) AU2017281082B2 (https=)
CA (1) CA3025081A1 (https=)
DK (2) DK3352754T3 (https=)
ES (2) ES2966094T3 (https=)
FI (1) FI3757107T3 (https=)
HR (2) HRP20201905T1 (https=)
HU (2) HUE052101T2 (https=)
IL (3) IL304979A (https=)
LT (2) LT3352754T (https=)
MX (2) MX391561B (https=)
PL (1) PL3757107T3 (https=)
PT (2) PT3352754T (https=)
RS (1) RS61239B1 (https=)
SG (2) SG11201810642XA (https=)
SI (2) SI3757107T1 (https=)
WO (1) WO2017223179A1 (https=)
ZA (1) ZA201808506B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
RS61239B1 (sr) * 2016-06-21 2021-01-29 Univ Columbia Inhibitori aldozne reduktaze i postupci korišćenja
IL272246B2 (en) * 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
WO2020167937A1 (en) * 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
WO2021071965A1 (en) * 2019-10-08 2021-04-15 Applied Therapeutics Inc. Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
WO2021222165A1 (en) * 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
US20240033263A1 (en) * 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2025219948A1 (en) 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) * 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
DE3684410D1 (de) 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en) 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
FI922308A7 (fi) 1989-12-15 1992-05-21 Pfizer Substituoituja oksoftalatsinyylietikkahappoja ja niiden anologeja
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
JPH11512095A (ja) 1995-08-28 1999-10-19 アメリカン・ホーム・プロダクツ・コーポレイション アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸
AU9253798A (en) 1997-09-23 1999-04-12 Novo Nordisk A/S Modules of protein tyrosine phosphatases (ptpases)
US6214991B1 (en) 1998-03-31 2001-04-10 The Institute For Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
EP1491541B1 (en) 2001-03-30 2007-01-24 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
WO2003061660A1 (en) 2002-01-23 2003-07-31 Eli Lilly And Company Melanocortin receptor agonists
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US7410981B2 (en) * 2002-06-14 2008-08-12 Takeda Pharmaceutical Company Limited Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
US20090305963A1 (en) 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
HRP20221430T1 (hr) 2010-07-16 2023-01-06 The Trustees Of Columbia University In The City Of New York Inhibitori aldozoreduktaze i njihova uporaba
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
RS61239B1 (sr) * 2016-06-21 2021-01-29 Univ Columbia Inhibitori aldozne reduktaze i postupci korišćenja
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection

Similar Documents

Publication Publication Date Title
JP2023171614A5 (https=)
ES2252978T3 (es) Agonistas 5ht2 serotonergicos para tratar el glaucoma.
JP2021063088A5 (https=)
US4963533A (en) Therapeutic application of dideoxycytidinene
JP2004527525A5 (https=)
YU88901A (sh) Derivati purina
CA2443089A1 (en) Antifungal suspension of micronized posaconazole
JP2005526107A5 (https=)
JP2005531607A5 (https=)
PL187085B1 (pl) Preparat farmaceutyczny do leczenia i/lub zapobiegania zakażeniom HIV
AR036127A1 (es) Composicion para administracion topica que comprende un inhibidor de interleucina 2 y un agente antimicrobiano y uso de estos ultimos para preparar dicha composicion
HUP0303315A2 (hu) Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények
JP2634202B2 (ja) 抗ウイルス性化合物
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
JP2024544538A5 (https=)
JP2590156B2 (ja) 経口投与用医薬組成物
JP2025114800A5 (https=)
RU2008146217A (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
EP4205742A1 (en) Composition for treating coronavirus-19 infection, comprising phenanthroindolizidine and phenanthroquinolizidine alkaloid derivative, optical isomer thereof, or pharmaceutically acceptable salt thereof as active ingredient
JP2022520410A5 (https=)
JP4737911B2 (ja) 点眼剤
JP2022527630A5 (https=)
IE912237A1 (en) Pharmaceutical preparations
RU2019137020A (ru) Составы со сниженным окислением
IL160082A0 (en) Quinoline derivatives and use thereof as antitumor agents